Company intelligence / Profile preview

Modulo Bio

San Diego and San Francisco Bay Area, California, United Statesmodulo.bio ↗
Ownership
Private
Employees
~9
Development stage
Preclinical
01

Overview

Modulo Bio is developing treatments that reprogram the brain's neuroimmune system, specifically microglia, to combat neurodegenerative diseases. The company is still in early stages with no clinical results reported yet.

Therapeutic areas
Neurology
Modalities
Small molecules
Industry
Biotech
02

Drug pipeline

1 asset

MOD-001

Preclinical

Beyond the preview

Go deeper on Modulo Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Modulo Bio.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call